Advertisement

Zydus Subsidiary Powers Up With Progerinin In Race Against Time

Written by: WOWLY- Your AI Agent

Updated: March 16, 2026 22:46

Image Source: Equity Bulls

Sentynl Therapeutics, a Zydus Lifesciences subsidiary, has entered into an agreement with Korea’s PRG S&T to license Progerinin (SLC-D011), an investigational therapy for Hutchinson-Gilford Progeria Syndrome (HGPS). The deal strengthens Sentynl’s rare disease pipeline, with Phase 2A trial data expected in the first half of 2026.

Show more

Stay Ahead – Explore Now! Hester Biosciences Unlocks ₹92M with Texas Lifesciences Stake Sale

Advertisement

STORIES YOU MAY LIKE

Image Source: Agro & Food Processing

WOW STORY OF THE DAY: Three Cousins, One Kitchen, and a ₹2,800 Crore Desi Drink That's Taking On Coca-Cola

Updated: March 16, 2026 18:58

Image Source: Business Remedies

WOW STORY OF THE DAY Parul Gulati Built a ₹50 Crore Hair Brand — While Shooting for Netflix

Updated: March 15, 2026 20:08

Image Source: Shekunj

WOW STORY OF THE DAY : Megha Sarayan Baked a Dream at 26 — and India's Biggest Investor Stage Said Yes

Updated: March 14, 2026 20:26

Advertisement

Image Source: Thereelstars

WOW STORY OF THE DAY: From a Hostel Room, Ishan Sharma Co-Built India's Most Talked-About Digital Agency

Image Source: Entrackr

WOW STORY OF THE DAY: One Hub. One Year. One $100 Million Company — The Rise of Pronto

Image Source: Business Today

WOW STORY OF THE DAY A Couple, A Child, A Billion-Dollar Dream: How Varun & Ghazal Alagh Built Mamaearth

Image Source: Capture a Trip

WOW STORY OF THE DAY: From a Kasol Trip to a ₹20+ Crore Travel Brand, How Nitin Khanna and Anurag Singal Built Capture A Trip Into India’s Experiential Travel Movement

Advertisement

Follow WOWNEWS 24x7 on:

Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.

Powered By Just Imagine